 Home > Medical News > Latest Medical News > The National Medical Insurance Administration announced that the two pharmaceutical companies were assessed as "serious" untrustworthy

The National Medical Insurance Administration announced that the two pharmaceutical companies were assessed as "serious" untrustworthy

 Last Update: 2022-11-04
 Source: Internet
 Author: User

Tags

ondansetron medicine

polycarbonate price

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Zhongxin.
com, November 1 According to the WeChat public account of the "National Medical Insurance Bureau" on the 1st, entrusted by the National Medical Security Bureau, the National Medical Security Bureau's Pharmaceutical Price and Bidding and Procurement Guidance Center summarized the situation of pharmaceutical enterprises rated as "particularly serious" and "serious" untrustworthy in each province from July 1, 2022 to September 30, 2022, and announced as follows:

1.
Beijing Nengji Traditional Chinese Medicine Pieces Co.
, Ltd

According to the judgment of the Fengtai District People's Court of Beijing Municipality, Beijing Nengji Traditional Chinese Medicine Pieces Co.
, Ltd.
gave kickbacks or improper benefits to relevant personnel of a number of medical institutions in order to obtain additional trading opportunities, competitive advantages and sales quantities for the traditional Chinese medicine pieces it operated, equivalent to a total of more than 1.
98 million yuan
.
The starting time of the limitation standard for untrustworthy conduct is May 27, 2021, and the Beijing centralized pharmaceutical procurement agency assesses the enterprise as "serious" untrustworthy
in accordance with the provisions of the price procurement credit evaluation system.

2.
Linxia Fuyuan Pharmaceutical Co.
, Ltd

According to the judgment of the Linxia County People's Court of Gansu Province, Linxia Fuyuan Pharmaceutical Co.
, Ltd.
gave kickbacks or improper benefits to relevant personnel of medical institutions to obtain additional trading opportunities, competitive advantages and sales quantities for the drugs it operated, which was equivalent to more than 1,355,273 yuan
.
The starting time of the limitation standard for untrustworthy conduct is January 28, 2022, and the centralized pharmaceutical procurement agency in Gansu Province assesses the enterprise as "serious" untrustworthy
in accordance with the provisions of the price procurement credit evaluation system.
(China News Finance)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.